RU94045825A - Применение материала, полученного из mycobacterium vaccae для производства терапевтического средства для лечения психических заболеваний, способ лечения психических заболеваний, продукт, содержащий антигенный и/или иммунорегуляторный материал, фармацевтическое средство - Google Patents

Применение материала, полученного из mycobacterium vaccae для производства терапевтического средства для лечения психических заболеваний, способ лечения психических заболеваний, продукт, содержащий антигенный и/или иммунорегуляторный материал, фармацевтическое средство

Info

Publication number
RU94045825A
RU94045825A RU94045825/13A RU94045825A RU94045825A RU 94045825 A RU94045825 A RU 94045825A RU 94045825/13 A RU94045825/13 A RU 94045825/13A RU 94045825 A RU94045825 A RU 94045825A RU 94045825 A RU94045825 A RU 94045825A
Authority
RU
Russia
Prior art keywords
disease treatment
psychiatric disease
immunoregulating
production
product containing
Prior art date
Application number
RU94045825/13A
Other languages
English (en)
Other versions
RU2124367C1 (ru
Inventor
Лаусон Стэнфорд Джон
Gb]
Артур Уильям Рук Грэхам
Original Assignee
Юниверсити Колледж Лондон (Gb)
Юниверсити Колледж Лондон
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юниверсити Колледж Лондон (Gb), Юниверсити Колледж Лондон filed Critical Юниверсити Колледж Лондон (Gb)
Publication of RU94045825A publication Critical patent/RU94045825A/ru
Application granted granted Critical
Publication of RU2124367C1 publication Critical patent/RU2124367C1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • External Artificial Organs (AREA)
  • Soil Working Implements (AREA)
  • Storage Of Fruits Or Vegetables (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Предложено применение антигенного и/или иммунорегуляторного материала, полученного из Мусоbасtеrium vассае, в лечении психических заболеваний, сопровождающихся аутоиммунными реакциями, инициированными инфекцией, а также последствий хронических инфекций, имеющих иммунологическую природу (иных, нежели увеит).

Claims (1)

  1. Предложено применение антигенного и/или иммунорегуляторного материала, полученного из Мусоbасtеrium vассае, в лечении психических заболеваний, сопровождающихся аутоиммунными реакциями, инициированными инфекцией, а также последствий хронических инфекций, имеющих иммунологическую природу (иных, нежели увеит).
RU94045825A 1992-02-21 1993-02-19 Фармацевтическое средство для лечения психического заболевания, сосудистых заболеваний и их осложнений RU2124367C1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB929203814A GB9203814D0 (en) 1992-02-21 1992-02-21 Treatment of long term auto-immune conditions
GB9203814.0 1992-02-21
PCT/GB1993/000351 WO1993016727A1 (en) 1992-02-21 1993-02-19 Mycobacterium vaccae for treatment of long term autoimmune conditions

Publications (2)

Publication Number Publication Date
RU94045825A true RU94045825A (ru) 1997-02-20
RU2124367C1 RU2124367C1 (ru) 1999-01-10

Family

ID=10710862

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94045825A RU2124367C1 (ru) 1992-02-21 1993-02-19 Фармацевтическое средство для лечения психического заболевания, сосудистых заболеваний и их осложнений

Country Status (24)

Country Link
US (1) US5885588A (ru)
EP (2) EP0763361B1 (ru)
JP (1) JPH07506093A (ru)
KR (1) KR100275862B1 (ru)
AT (2) ATE151641T1 (ru)
AU (2) AU675421B2 (ru)
BG (1) BG99054A (ru)
BR (1) BR9305946A (ru)
CA (1) CA2130117A1 (ru)
CZ (1) CZ282651B6 (ru)
DE (2) DE69328503T2 (ru)
DK (2) DK0763361T3 (ru)
ES (2) ES2145968T3 (ru)
FI (1) FI943849A0 (ru)
GB (1) GB9203814D0 (ru)
GR (2) GR3024113T3 (ru)
HU (1) HU218347B (ru)
NO (1) NO311169B1 (ru)
NZ (1) NZ249518A (ru)
RO (1) RO117833B1 (ru)
RU (1) RU2124367C1 (ru)
SK (1) SK99994A3 (ru)
UA (1) UA35583C2 (ru)
WO (1) WO1993016727A1 (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9406301D0 (en) * 1994-03-30 1994-05-25 Univ London Immunotherapeutic agent and its use
IL110011A (en) * 1994-06-13 2004-09-27 Yeda Res & Dev Pharmacological preparations for the treatment of schizophrenia
GB9505658D0 (en) * 1995-03-21 1995-05-10 Univ London Hormone and growth factor mimetics
US6056964A (en) * 1995-03-29 2000-05-02 Stanford Rook Limited Immunotherapeutic agent and its use
US6160093A (en) * 1996-08-29 2000-12-12 Genesis Researth And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US6406704B1 (en) 1996-08-29 2002-06-18 Genesis Research And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
AU741016B2 (en) * 1996-08-29 2001-11-22 Genesis Research And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US5985287A (en) * 1996-08-29 1999-11-16 Genesis Research And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US6284255B1 (en) 1996-08-29 2001-09-04 Genesis Research & Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
DK0951289T3 (da) * 1996-12-18 2006-03-13 Stanford Rook Ltd Anvendelse af Mycobacterium vaccae til behandling af kronisk træthedssyndrom
US6878377B2 (en) 1996-12-18 2005-04-12 Stanford Rook Limited Mycobacterium vaccae for down-regulation of the Th2 activity of the immune system
US5968524A (en) * 1997-12-23 1999-10-19 Genesis Research & Development Corp. Methods and compounds for the treatment of immunologically-mediated psoriasis
JP2002514385A (ja) * 1997-12-23 2002-05-21 ジェネシス リサーチ アンド デベロップメント コーポレイション リミテッド ミコバクテリウム・バッケー由来の組成物およびその使用法
US6328978B1 (en) 1997-12-23 2001-12-11 Genesis Research & Development Corp. Ltd. Methods for the treatment of immunologically-mediated skin disorders
US6350457B1 (en) 1999-06-02 2002-02-26 Genesis Research & Development Corporation Limited Methods and compounds for the treatment of immunologically-mediated diseases using mycobacterium vaccae
WO2001010221A1 (en) * 1999-08-06 2001-02-15 Corixa Corporation Vaccines for the treatment of autoimmune disease
GB0010496D0 (en) * 2000-04-28 2000-06-14 Stanford Rook Ltd Treatment of conditions of the central nervous system
GB0106986D0 (en) * 2001-03-20 2001-05-09 Stanford Rook Ltd Immunotherapeutic agent
GB0106985D0 (en) * 2001-03-20 2001-05-09 Stanford Rook Ltd Immunotherapeutic agent
JP4875494B2 (ja) * 2003-11-14 2012-02-15 ユーシーエル バイオメディカ ピーエルシー 免疫調節物質

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8404280D0 (en) * 1984-02-17 1984-03-21 Stanford J L Biological preparations
IL71683A0 (en) * 1984-04-27 1984-09-30 Yeda Res & Dev Pharmaceutical compositions for treating arthritis type diseases comprising fractions obtained from mycobacteria
GB8919321D0 (en) * 1989-08-25 1989-10-11 Univ London Treatment of chronic inflammatory conditions
ATE154759T1 (de) * 1990-11-08 1997-07-15 Univ London Mycobacterium als adjuvans für antigene

Also Published As

Publication number Publication date
DE69309915D1 (de) 1997-05-22
NO943082L (no) 1994-10-17
WO1993016727A1 (en) 1993-09-02
EP0763361B1 (en) 2000-04-26
EP0763361A3 (en) 1997-03-26
DK0630259T3 (da) 1997-09-15
DE69328503T2 (de) 2000-08-24
ATE151641T1 (de) 1997-05-15
HU218347B (hu) 2000-08-28
EP0630259A1 (en) 1994-12-28
US5885588A (en) 1999-03-23
FI943849A0 (fi) 1994-08-22
NZ249518A (en) 1997-07-27
UA35583C2 (ru) 2001-04-16
SK99994A3 (en) 1995-05-10
HUT69941A (en) 1995-09-28
GR3024113T3 (en) 1997-10-31
DE69328503D1 (de) 2000-05-31
AU7188796A (en) 1997-02-06
CZ202394A3 (en) 1995-02-15
AU675421B2 (en) 1997-02-06
GR3033772T3 (en) 2000-10-31
GB9203814D0 (en) 1992-04-08
RU2124367C1 (ru) 1999-01-10
ATE192046T1 (de) 2000-05-15
NO943082D0 (no) 1994-08-22
JPH07506093A (ja) 1995-07-06
RO117833B1 (ro) 2002-08-30
AU3637793A (en) 1993-09-13
EP0763361A2 (en) 1997-03-19
ES2104131T3 (es) 1997-10-01
DE69309915T2 (de) 1997-07-24
CZ282651B6 (cs) 1997-08-13
HU9402422D0 (en) 1994-10-28
DK0763361T3 (da) 2000-08-07
EP0630259B1 (en) 1997-04-16
ES2145968T3 (es) 2000-07-16
KR100275862B1 (ko) 2000-12-15
NO311169B1 (no) 2001-10-22
AU706122B2 (en) 1999-06-10
CA2130117A1 (en) 1993-09-02
BG99054A (en) 1995-08-28
KR950700755A (ko) 1995-02-20
BR9305946A (pt) 1997-10-21

Similar Documents

Publication Publication Date Title
RU94045825A (ru) Применение материала, полученного из mycobacterium vaccae для производства терапевтического средства для лечения психических заболеваний, способ лечения психических заболеваний, продукт, содержащий антигенный и/или иммунорегуляторный материал, фармацевтическое средство
RU94038043A (ru) Применение замещенных производных аденина для лечения множественного склероза
DE69133516D1 (de) Behandlung von autoimmunkrankheiten durch orale verabreichung von autoantigenen
HUP0203084A2 (en) Use of baff receptor (bcma) as an immunoregulatory agent
IL65875A0 (en) Capsules containing the active principle of an allergen,and process for their preparation
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
DE3854741T3 (de) Behandlung von autoimmun-erkrankungen durch orale verabreichung von autoantigenen.
ATE157257T1 (de) Verstärkung der unterdrückungsregulation von autoimmunkrankheiten durch orale oder enterale verabreichung von autoantigenen
DE59209704D1 (de) 2-Aminomethyl-chromane als Wirkstoffe in Arzneimitteln zur Behandlung von Erkrankungen des Zentralnervensystems
KR960700742A (ko) 아토피성질환 치료약(atopic disease remedy)
AU8335291A (en) Drugs, their manufacture, and their use as painkillers and/or to treat inflammations in humans and animals
ES2058592T3 (es) El uso de sustancias activas fisiologicamente para la fabricacion de medicamentos para enfermedades cerebrales y neuronales.
RU92016463A (ru) Применение производных цистина для изготовления лекарственных препаратов с иммуномоделирующим действием, фармацевтические композиции на их основе
NO902800D0 (no) Fremgangsmaate for fremstilling av 11beta-aryl-4-oestrener.
ATE182271T1 (de) Arzneimittel zur behandlung von krebs, aids und viruserkrankungen
IL88971A (en) Disubstituted pyridines, process and intermediates, their preparation and pharmaceutical compositions containing them
ATE338819T1 (de) Antigenes protein aus malassezia
ATE122100T1 (de) Humaner monoklonaler antikörper und diesen enthaltende arzneimittelzusammensetzung zur behandlung von pseudomonasinfektionen.
ES2147200T3 (es) Uso de un veneno de himenopteros para la fabricacion de un medicamento para tratar infecciones por virus de adn.
RU94019991A (ru) Антибиотическая композиция
DE3775854D1 (de) Arzneimittel zur therapie von durch funktionelle und organische basen verursachten gehirnkrankheiten.
DE68901172D1 (de) (-)-2-pyrazolinverbindung, deren optischen aufspaltung und therapeutisches agens zur behandlung von zerebralen gefaesskrankheiten, diese verbindung als aktives ingredient enthaltend.
RU94046312A (ru) Применение биологически активных уреидопроизводных для лечения индуцируемых лентивирусами заболеваний, продукты, содержащие уреидопроизводные
KR880002535A (ko) 약제로서의 15-데옥시스퍼구알린의 용도
ATE71299T1 (de) Pharmazeutische zubereitung zur behandlung bakterieller infektionen.

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20050220